1. 157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma. (December 2022) Authors: Sweis, R.; Garralda, E.; Saavedra Santa Gadea, O.; Moore, K.N.; Davar, D.; Hamid, O.; Segal, N.H.; Evans, T.R.J.; Dar, M.; Yuan, Y.; Collins, L.; Kirk, P.B.; Karakuzu, O.; Lopez, J.S.; Melero, I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 176P Phase I study of INCB106385 alone or in combination with immunotherapy in advanced solid tumors. (December 2022) Authors: Italiano, A.; Saavedra Santa Gadea, O.; Papadopoulos, K.; Naing, A.; Gomez-Roca, C.A.; Mita, M.; Stein, M.; Rybicka, I.; van der Velden, M.; Zhang, P.; Smith, M.; Ivanova, O.; Loriot, Y. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗